What PhotoQ3 does

PhotoQ3 is a Japanese biotechnology company founded in September 2019 by Takao Hamakubo (University of Tokyo Professor Emeritus) and Yasuhiko Bando, headquartered in Chiyoda-ku, Tokyo with a research facility in Minato-ku, Tokyo. The company develops iTAP (intelligent Targeted Antibody Phototherapy), a platform that integrates photodynamic therapy (PDT) with antibody-toxin conjugates to overcome the endosomal escape bottleneck of conventional immunotoxins. Core technical components include a proprietary recombinant saporin expression system (10–100x higher yield than conventional methods), near-infrared photosensitizing dyes (max absorption 775nm, developed with the University of Tokyo School of Engineering), and flexible N/C-terminal saporin engineering for uniform-DAR immunotoxin production. The company's therapeutic pipeline targets lung cancer, brain tumors, and ovarian cancer, and it holds exclusive implementation rights to PTX3-Fc fusion protein technology (Patent No. 7867700) for infectious disease applications.

The company has two commercial vectors. First, a research-use antibody catalog of monoclonal antibodies (Anti-Robo1, Anti-Cadherin17, Anti-ASNS, Anti-RIG-I, Anti-NFAT, Anti-KLF2, Anti-Ets-1, Anti-DSCR-1) launched in September 2025, sold directly via website inquiry to academic and pharmaceutical researchers in Japan with undisclosed pricing. Second, an iTAP-based therapeutic development business that is pre-revenue and intended to generate future licensing royalties and co-development income from pharmaceutical partners. Supporting revenue streams include joint R&D services and platform access (e.g., collaboration with Tokushu Immuno Research Institute for anti-CD20 immunotoxin development) and an AMED-funded pediatric cancer research project with Kobe University.

PhotoQ3 has raised JPY 200 million via a January 2022 third-party allotment from DEFTA Partners (San Francisco) and completed a FUNDINNO equity crowdfunding campaign in early 2025. The company holds multiple granted patents (Japan No. 7769386, US patent for near-IR dye, Japan No. 7867700) with one new substance patent application filed in August 2025. Operations are Japan-centric, with an employee count of 1–10, scientific advisory support from global PDT authority Harubumi Kato (17th IPA Gold Medal recipient), and collaborations with Nippon Medical School, Kanagawa Dental University, and Tokushu Immuno Research Institute validating the platform across lung, head and neck, and CD20-positive lymphoma indications.

Name

PhotoQ3

Legal name

株式会社PhotoQ3

Website

https://photoq3.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

PhotoQ3 is a Japanese biotechnology company that develops iTAP, a light-activated platform combining immunotoxins and photodynamic therapy for cancer treatment, and sells research antibodies developed through that platform to academic and pharmaceutical customers in Japan.

Ownership category

akta.pro rank

Product category

Biopharmaceutical R&D

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Research antibodies
• Photodynamic therapy
• Immunotoxin development
• Recombinant saporin
• Cancer therapeutics

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Antibody Product Sales: PhotoQ3 sells a diverse portfolio of high-quality research antibodies developed through its iTAP technology platform. Products launched sequentially starting September 2025. Sales via direct inquiry/contact forms. Targets academic researchers and pharmaceutical companies.
2. Drug Discovery / Therapeutic Development: Core revenue model focused on developing iTAP-based cancer therapeutics. Revenue anticipated from licensing, co-development deals with pharmaceutical companies, and eventual therapeutic product commercialization. Company is in pre-revenue R&D stage.
3. Joint Research & Development Services: PhotoQ3 provides its saporin manufacturing and immunotoxin engineering platform to partners for co-development. Examples include collaboration with Tokushu Immuno Research Institute for anti-CD20 immunotoxin development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

PhotoQ3 develops the iTAP (intelligent Targeted Antibody Phototherapy) platform, which integrates immunotoxin targeting with photodynamic therapy to dramatically improve endosomal escape and cytosolic delivery of toxin payloads for cancer treatment. The company also manufactures and sells a portfolio of high-quality research-grade monoclonal antibodies developed through its proprietary saporin expression technology, and develops recombinant saporin as a core reagent for immunotoxin engineering.

Product overview

PhotoQ3 operates as a biopharmaceutical company offering a dual portfolio consisting of (1) research-use antibodies developed through their proprietary iTAP technology platform, including 19 distinct monoclonal antibodies targeting proteins such as Robo1, Cadherin17, ASNS, RIG-I, NFAT, KLF2, Ets-1, and DSCR-1, and (2) the iTAP technology platform itself, which combines immunotoxins with photodynamic therapy principles to enhance endosomal escape for cancer treatment applications. The company also manufactures recombinant Saporin, a ribosome-inactivating protein, using proprietary high-efficiency expression technology. Their therapeutic pipeline focuses on lung cancer, malignant brain tumors, and ovarian cancer using the iTAP modality.

Differentiator

Problem solved

Functional benefit

Products and services

• iTAP (intelligent Targeted Antibody Phototherapy) Platform Next-generation molecular delivery platform integrating photodynamic therapy into immunotoxins to enhance endosomal escape and enable efficient cytosolic delivery of payloads. Targeted at pharmaceutical partners and academic researchers developing cancer therapeutics for solid tumors (lung, brain, ovarian cancer).
• Recombinant Saporin A 30-kDa ribosome-inactivating protein (RIP) derived from Saponaria officinalis used as the toxin component in immunotoxin development. Manufactured via proprietary stable recombinant expression technology enabling 10-100x higher expression efficiency than conventional methods. Supplied to pharmaceutical and academic research organizations.
• Anti-Robo1 Antibody Monoclonal antibodies targeting Robo1, a neuronal axon guidance receptor. Available for academic researchers and pharmaceutical R&D scientists in applications including IHC, WB, IP, and Flow cytometry.
• Anti-Cadherin17 Antibody Monoclonal antibodies targeting Cadherin-17, a calcium-dependent cell adhesion molecule involved in tumor invasion and metastasis. For oncology research and cancer drug discovery applications.
• Anti-Asparagine Synthetase (ASNS) Antibody Monoclonal antibodies targeting asparagine synthetase, used for measuring ASNS protein levels in cancer cells and evaluating ASNase sensitivity in cancer therapy. For academic and pharmaceutical oncology research.
• Anti-RIG-I Antibody Monoclonal antibodies targeting RIG-I (Retinoic Acid-Inducible Gene I), a cytoplasmic pattern recognition receptor for RNA virus detection. For immunology and infectious disease research.
• Anti-NFAT Antibody Monoclonal antibodies targeting Nuclear Factor of Activated T cells (NFAT) transcription factors. For immunology and cell biology research applications.
• Anti-KLF2 Antibody Monoclonal antibody targeting KLF2 (Kruppel-like factor 2), a transcription factor essential for T cell survival, migration control, and vascular endothelial cell inflammation suppression. For immunology research.
• Anti-Ets-1 Antibody Monoclonal antibodies targeting Ets-1 transcription factor, involved in cancer invasion, metastasis, and autoimmune disease inflammation. For oncology and immunology research.
• Anti-DSCR-1 Antibody Monoclonal antibodies targeting DSCR1 (Down Syndrome Critical Region 1), a negative regulator of calcineurin signaling. For cell signaling and disease research.
• CD20-targeted Novel Immunotoxin (Co-development Program) Co-development immunotoxin therapeutic program for rituximab-resistant malignant lymphoma, combining Tokushu Immuno Research Institute's proprietary anti-CD20 antibody (BM-ca) with PhotoQ3's immunotoxin engineering platform. Targeted at pharmaceutical partners for further development.

Quantifiable outcome

• 10–100x higher saporin expression yield compared to conventional methods
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and moderate.

• Kanagawa Dental University (神奈川歯科大学)coreStrategic or Co-development Partner · 3 March 2026Joint research demonstrating iTAP efficacy in head and neck cancer using animal models. Results published in the journal Biomedicines (2026). Validates iTAP as a differentiated platform technology for solid tumors.
• University of Tokyo School of Engineering (東京大学工学系研究科)coreStrategic or Co-development Partner · 6 December 2025Collaborative research with Prof. Akimitsu Okamoto's laboratory to develop novel near-infrared photosensitizing dyes (max absorption 775nm) for iTAP. Resulted in joint publication and US patent grant.
• Tokushu Immuno Research Institute Co., Ltd. (株式会社特殊免疫研究所)coreStrategic or Co-development Partner · 1 July 2025Joint research agreement to develop a new immunotoxin for rituximab-resistant malignant lymphoma and CD20-positive immune cell diseases. Uses Tokushu's proprietary anti-CD20 antibody (BM-ca) combined with PhotoQ3's immunotoxin engineering platform.
• Japan Agency for Medical Research and Development (AMED)moderateStrategic or Co-development Partner · 23 June 2025PhotoQ3 participates in an AMED drug discovery foundational research project led by Kobe University Graduate School of Medicine. Project focuses on pediatric cancer using FFPE specimen proteomics and next-generation drug discovery, where iTAP technology is applied.
• Nippon Medical School (日本医科大学)coreStrategic or Co-development Partner · 24 January 2023Collaboration on lung cancer iTAP therapy research, led by Prof. Jitsuo Usuda (Thoracic Surgery). Clinical needs aligned with PhotoQ3's technology development. Resulted in peer-reviewed publication.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• ADC Therapeutics: Clinical-stage biotech focused on antibody-drug conjugates for hematologic and solid tumors. Closely comparable as a focused ADC developer whose pipeline is built around overcoming delivery and resistance challenges for antibody-targeted payload therapies.
• ImmunoGen (AbbVie): Pioneer of ADC technology (Elahere/DM4 platform), acquired by AbbVie in 2024. Direct peer in antibody-targeted cytotoxic payload chemistry and oncology development.
• Mersana Therapeutics: Clinical-stage biotech developing next-generation ADC platforms with novel payloads and linkers designed to address delivery and tolerability limitations. Closely comparable as an emerging player seeking differentiation through platform-level chemistry innovation.
• Daiichi Sankyo: Japanese major pharmaceutical company and ADC platform leader behind Enhertu, the most commercially successful ADC to date. Directly comparable as a developer of antibody-conjugate therapeutics with global commercial reach, and the most likely strategic acquirer/partnership counterparty for an iTAP-style platform.
• Philogen: Clinical-stage biotech developing antibody-cytokine fusion products (e.g., L19-TNF, L19-IL2) for oncology. Comparable as a developer of antibody-targeted therapeutics with restricted payloads and academic/spinout DNA similar to PhotoQ3.

Broad incumbents

• Seagen (Pfizer): Leading ADC developer (Adcetris, Padcev) now part of Pfizer. A broadly comparable major player in antibody-conjugate oncology whose commercial pipeline dwarfs early-stage entrants in the same category.
• AstraZeneca: Global pharma with major ADC franchise (Enhertu co-development with Daiichi Sankyo, Datroway). Comparable as a global ADC acquirer/partner and as the leading commercial force behind antibody-targeted cytotoxic oncology therapy.

Emerging players

• Bolt Biotherapeutics: Preclinical/early-clinical developer of immunostimulatory antibody conjugates (ISACs) that combine antibody targeting with innate immune activation. Comparable as a smaller-stage platform company working on mechanism-improved conjugates for solid tumors.
• Theralase Technologies: Clinical-stage developer of photodynamic therapy (Ruvidar/PBA) for oncology and anti-infective applications. Comparable as a specialist PDT platform player advancing light-activated therapeutics toward commercial and clinical use.

Regional players

• PeptiDream: Japanese biotech specializing in peptide discovery and constrained peptide-based therapeutics for pharma partners. Comparable regional Japanese platform-biotech that monetizes platform technology through licensing to global pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=-Sw-3vbamhc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PhotoQ3